REG - IXICO plc - Issue of Equity

IXICOAnnouncement

07/01/2021 07:02

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210107:nRSG8391Ka&default-theme=true

RNS Number : 8391K  IXICO plc  07 January 2021

 

 

IXICO plc

 
("IXICO" or the "Company")

 

Issue of Equity

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in
neuroscience, announces that it has made an application to the London Stock
Exchange for the admission to trading on AIM of 45,176 new ordinary shares of
1p each ("New Shares") to satisfy the exercise of options.

 

The New Shares are expected to be admitted to trading on AIM on 12 January
2021.

 

Total voting rights

 

Application has been made for admission to trading on AIM of 45,176 New
Shares.  Admission of the New Shares on AIM is expected to become effective
at 8.00 a.m. on 12 January 2021, following which there will be in total
47,136,468 ordinary shares in the capital of the Company in issue, each
carrying equal voting rights.

 

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, IXICO under the FCA's
Disclosure and Transparency Rules.

 

For further information please contact:

 

 IXICO plc                                               +44 (0)20 3763 7498
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Russell Kerr (Sales

 Walbrook PR Ltd    +44 (0)20 7933 8780

 Paul McManus / Lianne Cawthorne /     IXICO@walbrookpr.com
 Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to
advance medicine and human health by turning data into clinically meaningful
information, providing valuable new insights in neuroscience and our goal is
to be a leading proponent of artificial intelligence in medical image
analysis. We will achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform, to improve
the return on investment in drug development and reduce risk and uncertainty
in clinical trials for our pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.IXICO.com)  and
follow us on Twitter @IxicOplc

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFLFVDLEIRIIL